Immunotherapy with or without radiation for liver cancer
Part of Cancer clinical trials.
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 19 years old.
- You must have liver cancer that cannot be removed by surgery and has spread into major blood vessels (like the portal vein or hepatic vein).
- You must have at least one tumor that can be measured on a scan.
- Your liver function must be well-preserved (Child-Pugh class A).
- You must be able to take care of yourself (ECOG score 0 or 1).
- You cannot have had more than one prior treatment with drugs that work throughout the body, and you cannot have had radiation to the liver before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main blood vessel of the liver (portal vein). The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.